Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of Wednesday, August 5, 2026.
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shoulder Innovations, Inc. (SI) | $468.68M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $440.37M | 77.61 | 31.29 | 25.88 | 27.59 |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.26B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 20.92 | 40.29 | 511.88 | 511.88 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.76B | N/A | 23.81 | 50.79 | 57.43 |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.06B | N/A | 61.96 | 88.48 | 88.48 |
| Oscar Health, Inc. (OSCR)vs › | $7.81B | N/A | 60.92 | 60.92 | 60.92 |
| Tempus AI, Inc. (TEM)vs › | $8.18B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.23B | 38.80 | 70.79 | 211.46 | 3741.39 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$22.60
Forward EPS (Est.)
$-1.71
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
